Evaluating the One-Year Efficacy of Combined Anti-VEGF and Dexamethasone Implant Treatment for Macular Edema in Retinal Vein Occlusions

11 June 2023: Clinical Research

Fengmei Ren ^1B* , Hui Gong ^1D* , Han Zhang ^1D* , Xiaoguang Zhang ^1E , Xiaolin Liu ^1F , Peifeng Gao ^1D , Junying Li ^2G* , Guisen Zhang ^1AE*

DOI: 10.12659/MSM.939277

Med Sci Monit 2023; 29:e939277

Table 3 Overall subjects’ baseline and follow-up of variables.

	Baseline	1 month	2 months	3 months	6 months	12 months	P
BCVA (LogMar)	0.31±0.22	0.39±0.24	0.44±0.24	0.44±0.22	0.46±0.21	0.39±0.23
IOP (mmHg)	16.03±2.67	16.40±2.10	17.77±3.06	16.82±2.21	15.91±1.91	16.12±2.24	0.007
CRT (μm)	650.03±180.56	376.50±111.29	378.26±142.86	380.74±118.68	374.00±98.27	345.56±63.71
Baseline SCP	45.34±4.94	40.99±7.48	43.29±5.83	43.60±4.37	46.71±3.61	44.49±4.48	0.001
Baseline DCP	44.52±4.47	42.18±6.10	43.07±6.29	45.30±5.73	46.39±3.41	45.42±5.23	0.015
FAZ area (mm)	0.32±0.22	0.30±0.11	0.36±0.17	0.33±0.17	0.34±0.09	0.35±0.15	0.435
FAZ circumference (mm)	2.17±0.73	2.19±0.37	2.31±0.55	2.15±0.51	2.18±0.36	2.18±0.59	0.673
FAZ – foveal avascular zone; CRT – central retinal thickness; SCP – superficial capillary plexus; DCP – deep capillary plexus; IOP – intraocular pressure; BCVA – best corrected visual acuity.